# of Displayed Technologies: 20 / 24

Applied Category Filter (Click To Remove): Clinical Area


Categories

Unveiling Unreported Pain: A Systematic Approach for Enhanced Patient Care
TS-064835 — The Need In healthcare, accurately assessing and managing pain is paramount for patient well-being and treatment efficacy. However, conventional methods of pain assessment rely heavily on verbal communication from patients, which poses challenges for individuals unable to express their pain verball…
  • College: College of Nursing
  • Inventors: Monroe, Todd
  • Licensing Officer: Taysavang, Panya

Transducin β-like protein 1 X-Linked Selective Degraders as Anti-cancer Therapeutics
TS-062685 — Cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, or nearly one in six deaths. The most common cancers are breast, lung, colon and rectum and prostate cancers. The Need Current cancer treatments mainly rely on chemotherapy, radiation, surgery and bon…
  • College: College of Pharmacy
  • Inventors: Cheng, Xiaolin; Alinari, Lapo; Li, Pui-Kai "Tom"; Yang, Rui
  • Licensing Officer: Taysavang, Panya

E-Cadherin-based Oncolytic Viral Cancer for Glioblastoma
TS-062682 — Glioblastoma (GBM) is the most common malignant brain tumor accounting for 47.7% of all brain cancers. Unfortunately, treatments are limited, and survival is poor, with approximately 40% living the first-year post-diagnosis and 17% in the second year. The Need Oncolytic viruses (OVs) are a prom…
  • College: College of Medicine (COM)
  • Inventors: Yu, Jianhua; Caligiuri, Michael; Xu, Bo
  • Licensing Officer: Taysavang, Panya

Selective Estrogen Receptor Beta Agonists
TS-062681 — According to the American Cancer Society, breast cancer is the most common cancer for women in the US, except for skin cancer. It comprised about 30% of all new female cancers each year. While breast cancer death rates have decreased over the last several decades, it remains the second leading cause…
  • College: OSU Wexner Medical Center
  • Inventors: Bennett, Chad; Wang, Dasheng
  • Licensing Officer: Taysavang, Panya

Selective Estrogen Receptor Beta Agonists
TS-062680 — According to the American Cancer Society, breast cancer is the most common cancer for women in the US, except for skin cancer. It comprised about 30% of all new female cancers each year. While breast cancer death rates have decreased over the last several decades, it remains the second leading cause…
  • College: College of Pharmacy
  • Inventors: Bennett, Chad; Wang, Dasheng
  • Licensing Officer: Taysavang, Panya

An innovative platform to enhance the efficacy of oncolytic virotherapy for cancer treatment through E-cadherin
TS-062679 — Glioblastoma (GBM) is the most common malignant brain tumor accounting for 47.7% of all brain cancers. Unfortunately, treatments are limited, and survival is poor, with approximately 40% living the first-year post-diagnosis and 17% in the second year. The Need Oncolytic viruses (OVs) are a prom…
  • College: College of Medicine (COM)
  • Inventors: Yu, Jianhua; Caligiuri, Michael; Xu, Bo
  • Licensing Officer: Taysavang, Panya

Nanobody-based Protein Degraders for the Treatment of Neurodegenerative Diseases
TS-062678 — Neurodegenerative diseases including Alzheimer's and Parkinson’s diseases, amyotrophic lateral sclerosis (ALS), prion diseases, and among others affect millions of people in the US. These diseases are relentless, often fatal, and affect fundamental functions – things like moving, bre…
  • College: College of Medicine (COM)
  • Inventors: Chu, Nam; Le, Nhat
  • Licensing Officer: Taysavang, Panya

Bi-specific T-Cell Engagers as Anti-cancer Therapeutics
TS-062677 — Cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, or nearly one in six deaths. The most common cancers are breast, lung, colon and rectum and prostate cancers. The Need Current cancer treatments mainly rely on chemotherapy, radiation, surgery and bon…
  • College: College of Medicine (COM)
  • Inventors: Caligiuri, Michael; Chan, Wing; Yu, Jianhua
  • Licensing Officer: Taysavang, Panya

Nras Mouse Melanoma Cell Lines
TS-049491 — Dr. Christin Burd's lab at The Ohio State University has developed a set of Nras-mutant mouse melanoma cell lines that can be used for preclinical tumor immunology and cancer biology studies.
Studies show that 15-30% of melanomas are Nras driven and 60% of melanomas are Braf driven. Dr. Christin Burd's lab at The Ohio State University has developed a set of Nras-mutant mouse melanoma cell lines that complement a set of Braf cell lines developed by Marcus Bosenberg at Yale Universit…
  • College: College of Medicine (COM)
  • Inventors: Burd, Christin; Murphy, Brandon
  • Licensing Officer: Taysavang, Panya

Mobile Application to Reduce the Risk of Narcotics Abuse Through Patient and Provider Empowerment
TS-041604 — This mobile application for pain management provides simple tools for patients, providers and researchers to use during clinical trials. The app not only tracks the efficacy of each patient's treatment, it can provide additional information to supplement and support the needs of the clinical trial.
The recent opioid epidemic has devastated American cities and kills 91 Americans per day. 80% of these addicts start with prescription pain killers. Preventative strategies to lower opioid use must be developed as most state adopted regulatory measures have failed. The development of such preventa…
  • College: College of Medicine (COM)
  • Inventors: Chandawarkar, Rajiv; Capek, Allison
  • Licensing Officer: Taysavang, Panya

A Small Molecule That Disperses Salmonella Biofilms
TS-041469 — A new compound to eliminate Salmonella biofilms to reduce typhoid fever.
The bacterium Salmonella enterica serovar Typhi (S. Typhi) is the causative agent of typhoid fever – infecting and killing an estimated 21 million and 200,000 individuals each year, respectively. Individuals contract the disease by consuming food or water contaminated with the etiologic agent …
  • College: College of Medicine (COM)
  • Inventors: Gunn, John; Huggins, William; Kuo, Laura; Melander, Christian
  • Licensing Officer: Taysavang, Panya

Identifying the level of lupus patients’ comprehension of their medication regimens and disease outcomes
TS-040132 — A questionnaire used to understand a patient’s comprehension of their personalized medication plan and the disease fluctuation of systemic lupus erythematous (SLE).
Systemic lupus erythematous (SLE) is an autoimmune disease in which the body’s immune system attacks healthy tissue in its own body. The disease has a prevalance of twenty to 150 cases per 100,000 individuals, and is more common in females than in men. This chronic disease has no cure, and s…
  • College: College of Medicine (COM)
  • Inventors: Meara, Alexa; Ardoin, Stacy; Peters, Ellen
  • Licensing Officer: Taysavang, Panya

Perivascular Drug Delivery Nanoplatform for Preventing Restenosis After Open Surgery
TS-039004 — Pericelle: a nanoparticle based perivascular drug delivery system to prevent stenosis and failure in vascular reconstruction surgeries.
Imaging and re-intervention procedures, necessary to maintain open blood vessels following vascular reconstruction surgery, are expensive. For example, the cost of maintenance for an arteriovenous (AV) fistula used in hemodialysis access has been estimated at $15,000/year. In bypass and AV fistula…
  • College: College of Medicine (COM)
  • Inventors: Kent, K. Craig; Chen, Guojun; Gong, Shaoqin; Guo, Lianwang; Shi, Xudong
  • Licensing Officer: Taysavang, Panya

Family HealthLink: A Health Risk Assessment Tool
TS-037825 — An online interactive tool that helps a patients and physicians assess a likelihood of cancer or heart disease, based on family history.
Physician documentation of family history in the EPIC® EMR for breast and ovarian cancer has been a common practice for many years, but documentation and assessment for other cancer types (and extended family history) have remained sparse and incomplete (Sweet, Sturm et al. 2015). In addition …
  • College: College of Medicine (COM)
  • Inventors: Sweet, Kevin; Newman, David "David"; Sturm, Amy; Westman, Judith "Judy"
  • Licensing Officer: Taysavang, Panya

Novel Small-Molecule Integrin-linked Kinase/Phosphoinositide-dependent Protein Kinase-2 Inhibitors
TS-037647 — A novel set of molecules that inhibit integrin-linked kinase in order to suppress tumor cell growth and metastasis.
The Akt signaling pathway is responsible for apoptosis, cell proliferation, and metabolism. In tumor cells, this pathway is up-regulated and aids in promoting cancer cell survival. Complete activation of Akt pathway requires phosphorylation at two amino-acid residues, which are phosporylated by se…
  • College: College of Pharmacy
  • Inventors: Chen, Ching-Shih; Kulp, Samuel; Lee, Su-Lin
  • Licensing Officer: Taysavang, Panya

Potential uses of IgG Fc for treating human diseases
TS-036778 — Infectious diseases present a problem for treatment, with concerns for the overuse of antibiotic medicine, inefficiency of modern medicines, and a need in the market for novel technologies that will target and work in conjunction with the host immune system, rather than depending on external mecha…
  • College: College of Medicine (COM)
  • Inventors: Dai, Hongsheng; Caligiuri, Michael; Yu, Jianhua
  • Licensing Officer: Taysavang, Panya

Biomimetic Nanoplatform to Deliver Anti-Restenotic Therapeutics
TS-036654 — A stent-free delivery platform for reducing arterial plaques.
Cardiovascular disease is the leading cause of death in the United States, resulting in more than 600,000 deaths and a significant contributor to overall healthcare costs. Over 28 million Americans are diagnosed with heart disease and contribute more than $30 billion in healthcare-related expenses. …
  • College: College of Medicine (COM)
  • Inventors: Kent, K. Craig; Chen, Guojun; Gong, Shaoqin; Guo, Lianwang; Urabe, Go; Wang, Bowen
  • Licensing Officer: Taysavang, Panya

Anti-NCL Immunoagent for Cancer Diagnosis and Therapy
TS-015251 — Nucleolin (NCL) is up-regulated in cancer cells, and modulates pro-tumorigenic pathways and chemoresistance. This anti-NCL agent binds and blocks NCL signaling, and may be optimized as cancer therapeutic and diagnostic tool.
Despite huge advancements in detection and treatment, cancer remains a top world health concern. One of the major limitations of current technology is adequately detecting tumor margins and micrometastases. Even with aggressive tumor resection and adjuvant chemotherapy or radiotherapy, tumor cells…
  • College: College of Medicine (COM)
  • Inventors: Palmieri, Dario; Croce, Carlo
  • Licensing Officer: Taysavang, Panya

Estrogen Receptor Beta Agonist Compounds
TS-015086 — Estrogen Receptor Beta Agonists for the treatment of breast, colon, and prostate cancers as well as inflammatory diseases.
There is a large emphasis on the need for novel and more effective cancer therapeutics, since there were nearly 600,000 cancer deaths in the United States in 2016 alone. One method for therapy of prostate, breast, and colon cancer that has been gaining traction is the targeting of estrogen recepto…
  • College: College of Pharmacy
  • Inventors: Tjarks, Werner; Bartunek, Petr; Sedlak, David
  • Licensing Officer: Taysavang, Panya

Mutant Hydrogenase Bacteria for Use against Enteric Pathogens
TS-015013 — Hydrogenase enzyme deficient bacterial strains that may be used as vaccines or attenuating agents for enteropathogenic diseases.
Enteric pathogens are responsible for an estimated two million deaths annually and cause millions more cases of diarrheal illness even in developed countries. When an individual contracts an enteric pathogen such as S. typhimurium, the infected individual will continue to shed the pathogen for up …
  • College: College of Medicine (COM)
  • Inventors: Gunn, John
  • Licensing Officer: Taysavang, Panya

Show More Technologies

Loading icon